NCT01553175

Studying Gene Expression in Samples From Patients With Rhabdoid Tumors

Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 25 (estimated)
• Sponsor: Children's Oncology Group · Network
• Sex: All
• Age: 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.

Detailed description

OBJECTIVES: * To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors. * To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors. * To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression. * To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors. * To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples. OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.

Conditions

• Brain and Central Nervous System Tumors
• Kidney Cancer

Interventions

Type	Name	Description
GENETIC	DNA analysis
GENETIC	gene expression analysis
GENETIC	mutation analysis
GENETIC	protein expression analysis
OTHER	immunohistochemistry staining method
OTHER	laboratory biomarker analysis

Timeline

• Start date: 2012-03-01
• Primary completion: 2016-07-01
• First posted: 2012-03-14
• Last updated: 2016-07-14